Brenda McCollum
ID:
|
Muslims and Islam in Buganda, ca. 1900 - 1962
REFNo: SS950ES
I seek to examine the Muslim experience of colonialism in the Kingdom of Buganda.
|
USA |
2021-11-23 |
2024-11-23 |
Social Science and Humanities |
Non-Clinical Trial |
Degree Award |
|
Rebecca Nalwanga Nalwanga
ID:
|
Exploring the Social and Institutional Dimensions of Disability in Primary Education: The Case of Inclusive Development in Uganda
REFNo: SS985ES
This research project aims to better understand the relationship between social development and disability in low-income countries. To achieve this objective, the research project will focus on how the experiences and positionality of primary school learners with a disability intersect with social development, education and democracy, and how these intersections can inform policy and practices to advance social, economic and political development in a low-income country such as Uganda.
|
Uganda |
2021-11-22 |
2024-11-22 |
Social Science and Humanities |
Non-Clinical Trial |
Degree Award |
|
Faith Masette Bisikwa
ID:
|
Exploring Classroom Assessment Practices and its Impact on Preservice Teachers’ self-efficacy in a selected Primary Teachers college, Uganda
REFNo: SS993ES
I used questions instead of objectives
Main Question; How do tutors’ classroom assessment practices impact preservice teacher’s self-efficacy?
Subsidiary questions;
1.What are the common classroom assessment practices in Ugandan Primary teachers’ colleges?
2.How is classroom assessment, practiced in this PTC?
3.What is the relationship between assessment practices and preservice teacher’s self-efficacy?
4.How best can classroom assessment practices be done in PTCs to improve Preservice teachers’ self-efficacy?
|
Uganda |
2021-11-22 |
2024-11-22 |
Social Science and Humanities |
Non-Clinical Trial |
Degree Award |
|
Cissy Kityo
ID: UNCST-2021-R013663
|
ACTIV-2/A5401: Adaptive Platform Treatment Trial for Outpatients with COVID-19
(Adapt Out COVID)
REFNo: HS1813ES
1.1 Co-Primary Objectives
1.1.1 Phases II and III: To evaluate safety of the investigational agent.
1.1.2 Phase II: To determine efficacy of the investigational agent to reduce the duration of COVID-19 symptoms through study day 28.
1.1.3 Phase II: To determine the efficacy of the investigational agent to increase the proportion of participants with nasopharyngeal (NP) SARS-CoV-2 RNA below the lower limit of quantification (LLoQ) at study days 3, 7, and 14.
1.1.4 Phase III: To determine if the investigational agent will prevent the composite endpoint of hospitalization due to any cause or death due to any cause through study day 28. Hospitalization is defined as ≥24 hours of acute care, in a hospital or similar acute care facility, including Emergency Rooms or temporary facilities instituted to address medical needs of those with severe COVID-19 during the COVID-19 pandemic.
1.2 Secondary Objectives
1.2.1 Phases II and III: To determine whether the investigational agent reduces a COVID-19 Severity Ranking scale based on COVID-19-associated symptom burden (severity and duration), hospitalization, and death, through study day 28.
1.2.2 Phase II and III: To determine whether the investigational agent reduces the progression of COVID-19-associated symptoms.
1.2.3 Phase II and III: To determine if the investigational agent reduces levels of SARS-CoV-2 RNA in NP swabs.
1.2.4 Phase III: To determine the efficacy of the investigational agent to increase the proportion of participants with NP SARS-CoV-2 RNA below the LLoQ at study day 3.
1.2.5 Phase II: To determine the pharmacokinetics of the investigational agent.
1.2.6 Phase II: To determine efficacy of the investigational agent to obtain pulse oximetry measurement of ≥96% through day 28.
1.2.7 Phase III: To determine if the investigational agent will prevent the composite endpoint of hospitalization due to any cause or death due to any cause through study week 72.
1.2.8 Phase III: To evaluate if the investigational agent reduces the time to sustained symptom resolution through study day 28.
|
Uganda |
2021-11-22 |
2024-11-22 |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Francis Ssali
ID: UNCST-2021-R012134
|
A Phase 2, Open-label, Single-arm, Multicentre Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Efficacy of Switching to RPV Plus Other ARVs in HIV-1-infected Children (Aged 2 to less than 12 years) who are Virologically Suppressed (TMC278HTX2002)
REFNo: HS1815ES
Primary Endpoints
• Area under the plasma concentration-time curve from the time of administration up to 24 hours post-dose of RPV, as derived from the intensive PK assessments.
• Incidence of grade 3/4 AEs, SAEs, HIV-related events (including acquired immune deficiency syndrome [AIDS]-defining illnesses and Stage-3-defining Opportunistic Illnesses in HIV Infection), and AEs leading to discontinuation of study intervention through 24 weeks of study treatment.
Secondary Endpoint
• Incidence and severity of AEs/HIV-related events and their relatedness to RPV through 24 and 48 weeks of study treatment.
• Change from baseline Movement.
• Viral genotype at the time of virologic failure through 24 and 48 weeks of study treatment.
• Treatment adherence, as assessed by the Pediatric European Network for the Treatment of AIDS (PENTA) adherence questionnaire and by study intervention accountability, through 24 and 48 weeks of study treatment.
|
Uganda |
2021-11-22 |
2024-11-22 |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
| View |
|
Sort By: |
|
|
|
| |
|